CCTG

MAC.12 | TAILORx

NCT00310180

MAC.12

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) (TAILORx)

Status:

Closed to Accrual

26459-200.png

III

Phase

Line of Therapy.png

Adjuvant

Line of Therapy

Disease Stage.png

Early Cancer

Disease Stage

Target.png

Biomarker(s)

ER+, HER2-

Investigational

Product

Tamoxifen, Anastrozole, Letrozole, or Exemestane

Treatment Arms

o Experimental: Group 1 (Oncotype DX recurrence score =< 10)

o Experimental: Group 2, Arm I (experimental)

o Active Comparator: Group 2, Arm II (standard)

o Experimental: Group 3 (Oncotype DX recurrence score >= 26)